Please use this identifier to cite or link to this item:
|Title:||Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer|
|Authors:||Nicole Tsang, Y.-H.|
Wee Ong, C.
|Citation:||Nicole Tsang, Y.-H., Wu, X.-W., Lim, J.-S., Wee Ong, C., Salto-Tellez, M., Ito, K., Ito, Y., Chen, L.-F. (2013-03-21). Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer. Oncogene 32 (12) : 1488-1496. ScholarBank@NUS Repository. https://doi.org/10.1038/onc.2012.178|
|Abstract:||Emerging evidence demonstrates that RUNX3 is a tumor suppressor in breast cancer. Inactivation of RUNX3 in mice results in spontaneous mammary gland tumors, and decreased or silenced expression of RUNX3 is frequently found in breast cancer cell lines and human breast cancer samples. However, the underlying mechanism for initiating RUNX3 inactivation in breast cancer remains elusive. Here, we identify prolyl isomerase Pin1, which is often overexpressed in breast cancer, as a key regulator of RUNX3 inactivation. In human breast cancer cell lines and breast cancer samples, expression of Pin1 inversely correlates with the expression of RUNX3. In addition, Pin1 recognizes four phosphorylated Ser/Thr-Pro motifs in RUNX3 via its WW domain. Binding of Pin1 to RUNX3 suppresses the transcriptional activity of RUNX3. Furthermore, Pin1 reduces the cellular levels of RUNX3 in an isomerase activity-dependent manner by inducing the ubiquitination and proteasomal degradation of RUNX3. Knocking down Pin1 enhances the cellular levels and transcriptional activity of RUNX3 by inhibiting the ubiquitination and degradation of RUNX3. Our results identify Pin1 as a new regulator of RUNX3 inactivation in breast cancer. © 2013 Macmillan Publishers Limited All rights reserved.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 20, 2018
WEB OF SCIENCETM
checked on Apr 23, 2018
checked on Mar 12, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.